<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04138589</url>
  </required_header>
  <id_info>
    <org_study_id>201900032</org_study_id>
    <nct_id>NCT04138589</nct_id>
  </id_info>
  <brief_title>Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function</brief_title>
  <acronym>ROOTS</acronym>
  <official_title>Real World Data of the Effect of Lumacaftor/Ivacaftor Therapy in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Marien Hospital Wesel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To obtain prospective real world data of the effect of lumacaftor/ivacaftor or tezacaftor/
      ivacaftor on small airway disease in children aged 6-18 years with cystic fibrosis (CF)
      homozygous for F508del. The effect of the medication on small airway disease is evaluated by
      measurement of multiple breath washout (MBW) with its outcome parameter lung clearance index
      (LCI) and the Perth-Rotterdam Annotated Grid Morphometric Analysis for CF (PRAGMA-CF)
      cpmputed tomography (CT) score. In addition the relation between changes in LCI and PRAGMA-CF
      score is evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center observational study. Duration 12 months after the start of lumacaftor/ ivacaftor
      or tezacaftor/ ivacaftor .

      To collect these data and to assist in clinical decisions regarding initiation and
      continuation of lumacaftor/ivacaftor or tezacaftor/ ivacaftor, the investigators of the CF
      center (Beatrix Children's Hospital, University Medical Center Groningen (UMCG), the
      Netherlands) developed an extensive protocol of testing before children aged 6-18 years start
      therapy and during the first year after start.

      The protocol includes the following tests: growth parameters, sweat test, lung function
      testing (spirometry, MBW, body plethysmography), blood test panel (AST, ALT, alkalic
      phosphatase (AF), total and direct bilirubin, LDH), fecal elastase, high resolution (HR)CT
      and CF quality of life questionnaires. These tests are repeated at regular intervals.

      Multi-center observational study. Duration 12 months after the start of lumacaftor/ ivacaftor
      or tezacaftor/ ivacaftor .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in lung clearance index</measure>
    <time_frame>12 months</time_frame>
    <description>Change between t=0 and t=12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in PRAGMA-CF score</measure>
    <time_frame>12 months</time_frame>
    <description>Change between t=0 and t=12</description>
  </secondary_outcome>
  <other_outcome>
    <measure>percent predicted forced expiratory volume in 1 second</measure>
    <time_frame>12 months</time_frame>
    <description>t= 0 and t-=12</description>
  </other_outcome>
  <other_outcome>
    <measure>percent predicted forced vital capacity measured by spirometry</measure>
    <time_frame>12 months</time_frame>
    <description>Change between t=0 and t=12</description>
  </other_outcome>
  <other_outcome>
    <measure>Residual volume measured by blodypethysmography</measure>
    <time_frame>12 months</time_frame>
    <description>Change between t=0 and t=12</description>
  </other_outcome>
  <other_outcome>
    <measure>Residual volume/ total lung capacity measured by blodypethysmography</measure>
    <time_frame>12 months</time_frame>
    <description>Change between t=0 and t=12</description>
  </other_outcome>
  <other_outcome>
    <measure>Mid upper arm circumference in SDS</measure>
    <time_frame>12 months</time_frame>
    <description>Change between t=0 and t=12</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight SDS</measure>
    <time_frame>12 months</time_frame>
    <description>Change between t=0 and t=12</description>
  </other_outcome>
  <other_outcome>
    <measure>Sweat chloride level</measure>
    <time_frame>12 months</time_frame>
    <description>Change between t=0 and t=12</description>
  </other_outcome>
  <other_outcome>
    <measure>CF questionnaire revised respiratory domain</measure>
    <time_frame>12 months</time_frame>
    <description>Change between t=0 and t=12, scale 0-100</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cystic Fibrosis in Children</condition>
  <arm_group>
    <arm_group_label>CF patients aged 6-18 years homozygeous for delta F508</arm_group_label>
    <description>CF patients aged 6-18 years homozygeous for delta F508 starting with lumacaftor/ ivacaftor or tezacaftor/ ivacaftor</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients are included from the Beatrix Children's Hospital, UMCG, the Netherlands and the
        Marien Hospital Wesel, Germany
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children aged 6-18 years

          -  CF, Homozygote F508del confirmed by DNA analysis

          -  Considered for start of lumacaftor/ ivacaftor or tezacaftor/ivacaftor

        Exclusion Criteria:

          -  - Unable to perform acceptable, repeatable lung function tests
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Annelies M Zwitserloot, MD</last_name>
    <phone>+31625649950</phone>
    <email>a.m.zwitserloot@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brigitte WM Willemse, MD, phd</last_name>
    <phone>+31503616161</phone>
    <email>b.w.m.willemse@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Marien Hospital Wesel</name>
      <address>
        <city>DÃ¼sseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Gappa, MD, Phd</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatrix Children's Hospital, University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annelies M Zwitserloot, MD</last_name>
      <phone>+31625649950</phone>
      <email>a.m.zwitserloot@umcg.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <last_update_submitted>October 24, 2019</last_update_submitted>
  <last_update_submitted_qc>October 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>A.M. Zwitserloot</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>lumacaftor/ ivacaftor</keyword>
  <keyword>tezacaftor/ ivacaftor</keyword>
  <keyword>Multiple breath washout</keyword>
  <keyword>Lung clearance index</keyword>
  <keyword>PRAGMA CF score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plans to share IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

